Literature DB >> 12433817

Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors.

Thanh Huu Tran1, Lisa L Von Moltke, Karthik Venkatakrishnan, Brian W Granda, Megan A Gibbs, R Scott Obach, Jerold S Harmatz, David J Greenblatt.   

Abstract

The effect of microsomal protein concentration on the inhibitory potency of a series of CYP3A inhibitors was assessed in vitro using diazepam 3-hydroxylation (yielding temazepam) as an index of CYP3A activity. With diazepam concentrations fixed at 100 micro M, inhibition of temazepam formation by fixed concentrations of ritonavir, ketoconazole, itraconazole, OH-itraconazole, norfluoxetine, and fluvoxamine decreased substantially as active protein concentrations increased from 0.0625 to 3.0 mg/ml. However protein concentration had only a small effect on the inhibitory activity of fluconazole. Equilibrium dialysis indicated extensive microsomal binding of all inhibitors except fluconazole; binding increased with higher protein concentrations. Based on the CYP3A content of liver microsomes, decrements in inhibitory potency of stronger inhibitors (ketoconazole and ritonavir) could be explained by specific binding, whereas nonspecific binding is anticipated to account for the effect on weaker inhibitors (norfluoxetine and fluvoxamine). Thus, microsomal binding (specific, nonspecific, or a combination of both) may have a major effect on estimation of inhibitory potency of p450 inhibitors and may contribute to variations among laboratories. The effect can be minimized by use of the lowest possible microsomal protein concentration for in vitro studies of metabolic inhibition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12433817     DOI: 10.1124/dmd.30.12.1441

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  16 in total

1.  Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.

Authors:  Daniel R McMasters; Rhonda A Torres; Susan J Crathern; Deborah L Dooney; Robert B Nachbar; Robert P Sheridan; Kenneth R Korzekwa
Journal:  J Med Chem       Date:  2007-06-09       Impact factor: 7.446

2.  Structure-based prediction of the nonspecific binding of drugs to hepatic microsomes.

Authors:  Haiyan Li; Jin Sun; Xiaofan Sui; Zhongtian Yan; Yinghua Sun; Xiaohong Liu; Yongjun Wang; Zhonggui He
Journal:  AAPS J       Date:  2009-05-14       Impact factor: 4.009

3.  Drug Distribution. Part 1. Models to Predict Membrane Partitioning.

Authors:  Swati Nagar; Ken Korzekwa
Journal:  Pharm Res       Date:  2016-12-15       Impact factor: 4.200

Review 4.  Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Authors:  David J Greenblatt; Jerold S Harmatz
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

5.  Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.

Authors:  Hayley S Brown; Aleksandra Galetin; David Hallifax; J Brian Houston
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Concentration effect relationship of CYP3A inhibition by ritonavir in humans.

Authors:  Christine Eichbaum; Marianna Cortese; Antje Blank; Jürgen Burhenne; Gerd Mikus
Journal:  Eur J Clin Pharmacol       Date:  2013-06-09       Impact factor: 2.953

7.  Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

Authors:  Brian J Kirby; Ann C Collier; Evan D Kharasch; Dale Whittington; Kenneth E Thummel; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2011-03-15       Impact factor: 3.922

Review 8.  Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Authors:  Siamak Cyrus Khojasteh; Saileta Prabhu; Jane R Kenny; Jason S Halladay; Anthony Y H Lu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-19       Impact factor: 2.441

9.  Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.

Authors:  Huixin Yu; Jeroen J M A Hendrikx; Sven Rottenberg; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  AAPS J       Date:  2015-11-24       Impact factor: 4.009

Review 10.  Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Authors:  Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.